Acute on chronic itp
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information to deliver a thorough answer on acute on chronic ITP. Let me synthesize this.
Acute on Chronic ITP
Background & Classification
ITP (immune thrombocytopenia) is classified by duration and context:
| Phase | Definition |
|---|---|
| Newly diagnosed | < 3 months from diagnosis |
| Persistent | 3–12 months |
| Chronic | > 12 months |
| Severe | Platelet count < 20,000/μL |
Chronic ITP is primarily an adult disease, 3× more common in women, with insidious onset — easy bruising, prolonged menses, mucosal bleeding, petechiae/purpura, and platelet counts typically 30,000–100,000/μL. — Rosen's Emergency Medicine, p. 5025
"Acute on chronic" ITP refers to a sudden, significant drop in platelet count in a patient with established chronic ITP — often triggered by infection, a new drug, surgery, or stress, resulting in bleeding risk out of proportion to their baseline.
Pathophysiology
Antiplatelet IgG autoantibodies bind platelet surface antigens (GPIIb/IIIa, GPIb/IX) → premature clearance by the reticuloendothelial system (primarily spleen) + immune-mediated suppression of megakaryocyte platelet production. — Washington Manual, p. 757
Common Triggers of Acute Exacerbation
- Viral infection (EBV, HIV, HBV, HCV, varicella, rubella)
- New drug (quinidine, vancomycin, linezolid, NSAIDs, anticonvulsants, abciximab)
- H. pylori infection
- Autoimmune flare (SLE, APS, rheumatoid arthritis)
- Lymphoproliferative disease progression
- Pregnancy
Clinical Presentation
- Worsening petechiae/purpura beyond baseline
- Mucocutaneous bleeding (gingival, epistaxis, menorrhagia)
- Platelet count < 20,000/μL → severe ITP
- Platelet count < 5,000/μL or internal/intracranial bleeding → emergency
- CNS bleeding risk rises sharply below 10,000/μL
Workup
- CBC with peripheral smear — confirm isolated thrombocytopenia, exclude platelet clumping, check for MAHA (TTP/HUS) or other cytopenias
- Reticulocyte count, LDH, haptoglobin — exclude hemolytic process
- Screen for triggers: HIV, HCV, HBV, H. pylori, ANA/anti-dsDNA
- Review medications — drug-induced ITP resolves with offending agent withdrawal
- Bone marrow biopsy is not routine but consider if additional CBC abnormalities, atypical features, or therapy failure — Washington Manual, p. 757
Management
Emergency / Life-Threatening Bleeding (platelet < 5,000/μL or internal bleed)
Simultaneous combination therapy:
- High-dose pulse corticosteroids: IV methylprednisolone 1 g/day × 3 days, or dexamethasone 40 mg IV/PO × 4 days
- IVIG: 1 g/kg IV × 1–2 doses (produces fastest platelet rise, superior to steroids alone)
- Platelet transfusion: 2–3× normal dose — note platelets will be rapidly consumed by circulating antibodies; repeat transfusions often required
- Anti-D immunoglobulin (WinRho): 50–75 mcg/kg — only in Rh(D)+ non-splenectomized patients; black-box warning for severe intravascular hemolysis — Tintinalli's Emergency Medicine, p. 1287–1289; Goldman-Cecil Medicine, p. 1128
For life-threatening bleeding unresponsive to above: consider TPO receptor agonist (eltrombopag, romiplostim, avatrombopag) — takes 5–14 days to effect, discuss with hematology urgently. Recombinant factor VIIa and plasmapheresis are no longer recommended. — Rosen's, p. 5031
Non-Emergency Exacerbation (platelet < 30,000/μL, minor bleeding)
| Option | Dose | Notes |
|---|---|---|
| Dexamethasone (preferred steroid) | 40 mg PO/IV × 4 days | Faster, deeper response vs prednisone |
| Prednisone | 1 mg/kg/day with taper | Over weeks |
| IVIG | 1 g/kg × 1–2 doses | Add if count < 10,000, sig. bleeding, or rapid rise needed |
IVIG + glucocorticoids → more sustained response than IVIG alone. — Rosen's, p. 5031
Second-Line / Refractory Chronic ITP (30–40% of patients relapse/become refractory)
| Therapy | Details | Response |
|---|---|---|
| Splenectomy | Removes primary site of Ab production + platelet destruction | Durable complete response ~65–70% |
| Rituximab | 375 mg/m² IV weekly × 4 doses (anti-CD20) | ~60% response; remission at 12 months ~25%; check HBV before use |
| TPO-RAs: romiplostim (SC weekly), eltrombopag/avatrombopag (oral daily) | Stimulate platelet production; effect in 2–3 weeks | >90% platelet improvement; risk of thrombosis, bone marrow fibrosis |
| Fostamatinib (Syk kinase inhibitor) | 100 mg BD → 150 mg BD if inadequate response at 4 wks | Stable response ~18% in heavily pre-treated patients; GI side effects, hypertension |
| Other immunosuppressants | Cyclophosphamide, azathioprine, cyclosporine, MMF, danazol, dapsone | Used in refractory/combination settings |
— Goldman-Cecil Medicine, pp. 1103–1128; Washington Manual, p. 758
Key Pearls
- Treat the trigger: eradicate H. pylori (can normalise platelets), treat HCV (direct-acting antivirals improve ITP), stop offending drug
- Platelet transfusion in ITP is for rescue only — it is not a treatment; transfused platelets are rapidly destroyed
- Before splenectomy: vaccinate against pneumococcus, meningococcus, H. influenzae type B (preferably ≥2 weeks prior)
- TPO-RAs are effective even post-splenectomy
- In pregnancy with acute ITP exacerbation: target platelet ≥ 30,000 (early/vaginal delivery), ≥ 50,000 (C-section), ≥ 80,000 (neuraxial anaesthesia) — Goldman-Cecil, p. 1244
This is a shared conversation. Sign in to Orris to start your own chat.